101 / 374
XXXIX
Congreso de la Sociedad Española de Inmunología Clínica y Alergología Pediátrica
101
dy in the hypereosinophilic syndro-
me with eosinophilic der- matitis. N
Engl J Med. 2003; 349:2334-9.
58.
Spergel J, Rothenberg M, Collins
M, et al. Reslizumab in children
and adolescents with eosinophilic
esophagitis: Results of a double
blind, randomized, placebo-contro-
lled trial. J. Allergy Clin Immunol
2012; 129:456-63.
59.
Straumann A, Conus S, Grzonka P,
et al. Anti-interleukin-5 antibody
treatment (mepolizumab) in active
eosinophilic esophagitis: a rando-
mised , placebo controlled, doble
blind trial. Gut. 2010; 59(1) 21-30.
60.
Rothenberg ME, Wen T, Greenberg
A, et al. Intravenous anti IL13 m Ab
QAX576 for the tratment of eosino-
philic esophagitis. J Allergy Clinic
Immunol. 2015; 135: 500- 7.
61.
Huo X, Zhang X, Yu C, et al. In
esophageal squamous cells ex-
posed to acidic bile salt medium,
omeprazole inhibits IL8 expressin
through effects on nuclear factor kB
and actuvator protein 1. Gut.2014
Jul; 63(7):1042-52.
62.
Wolf WA, Dellon ES, Shaheen NJ.
Esophageal disease. Gastrointest
Endosc 2014; 80:767.
for adult eosinophilic esophagitis: A
prospective multicenter study. J Aller-
gy Clin Immunol. 2014; 134:1093-9.
52.
Liacuras C, Wenner W Brwn K, et al.
Primary eosinophilic esophagitis in
children succesful treatment with
oral corticosteroids. J Pediatr Gas-
troentrol Nutri. 1998;26:380-5.
53.
Aceves SS, Bastian JF, Newbury
RO, et al. Oral viscous budesonidde
a potencial new therapy for eosino-
philic esophagitis in children. Am J
Gastroenterol 2007; 102:2271-9.
54.
Remedios M, Campbell C, Jones
DM, et al. Eosinophilic esophagitis
in adults: clini- cal, endoscopic, his-
tologic findings, and response to
treatment with fluticasone pro- piona-
te. Gastrointest Endosc. 2006; 63:3-12.
55.
Noel RJ, Putnam PE, Collins MH, et
al. Clinical and immunopathologic
effects of swallowed fluticasone for
eosinophilic esophagitis. Clin Gas-
troenterol Hepatol. 2004;2:56
56.
Garret JK, Jameson SC,Thomson B,
et al. Anti-interleukin-5 (mepolizu-
mab) therapy for hypereosinophilic
syndromes. J Allergy Clin Immunol.
2004; 113:115-9.
57.
Plotz SG, Simon HU, Darsow U, et
al. Use of an- ti-interleukin-5 antibo-